Article Text

Download PDFPDF
MHRA safety alert: hyoscine butylbromide (Buscopan) injection

Statistics from

The Medicines and Healthcare products Regulatory Agency (MHRA) reports that prescribing information for hyoscine butylbromide (Buscopan) injection has been updated to help to minimise the risk of serious adverse reactions in patients with cardiac disease.1

Hyoscine butylbromide, given intravenously or intramuscularly, is indicated in acute muscular spasm, as in renal or …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.